Business
Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
TORONTO, Sept. 9 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and...
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTORONTO, Sept. 9 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology\ncompany discovering and developing the next wave of antibody therapeutics,\ntoday announced that RiskMetrics ISS Canada, Canada's leading independent\nproxy firm, has indicated that they have no objection to the transaction, and\nare recommending that ARIUS shareholders and warrant holders vote FOR the\nproposed plan of arrangement whereby Roche will acquire all of ARIUS'\noutstanding shares and warrants.\n\n\n"The comprehensive review undertaken by RiskMetrics ISS Canada recommends\nthat ARIUS shareholders and warrant holders vote FOR the Arrangement and, in\nour opinion, provides significant independent validation that the transaction\nrepresents the best option for maximizing shareholder value," said Dr. David\nS. Young, President and Chief Executive Officer of ARIUS.\n\n\nA special meeting of ARIUS shareholders and warrant holders will be held\nat 10:30 a.m. Eastern Time on September 16, 2008 at the Suites at 1 King West,\nToronto, Ontario, Canada, M5H 1A1. ARIUS shareholders and warrant holders are\nencouraged to review the Notice of Special Meeting and Information Circular\nissued by the Company on August 12, 2008. The Information Circular provides,\namong other things, a detailed discussion of the process that led to the\nproposed Arrangement and the reasons behind ARIUS Board of Directors'\nunanimous recommendation that shareholders vote FOR the transaction. Pending\nthe receipt of court and shareholder approval, the transaction is expected to\nbe completed in late September.\n\n\nARIUS' Board asks shareholders and warrant holders to vote their proxy\nFOR the proposed Arrangement today by signing, dating and returning their\nproxies. The deadline for receiving proxies is September 12, 2008 at 5:00 p.m.\nEastern Time. If shareholders have any questions about the information\ncontained in the Information Circular or require assistance in completing\ntheir proxy forms, please contact ARIUS' proxy solicitation agent, The Laurel\nHill Advisory Group, toll-free at 1-888-270-2614.\n\n\nAbout ARIUS\n\n\nARIUS is a biotechnology company discovering and developing the next wave\nof antibody therapeutics. Established in 1999, ARIUS has built a proprietary\ntechnology platform, FunctionFIRST(TM), that rapidly identifies and selects\nantibodi...